Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MLR-1023

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
AIM MLR-1023, called Tolimidone when evaluated unsuccessfully by Pfizer for gastric ulcer disease, has been repurposed as a novel… Expand
Is this relevant?
Review
2020
Review
2020
Drug discovery requires the combination of medicinal chemistry and biology. In this article Chris Lipinski, the medicinal chemist… Expand
Is this relevant?
Review
2017
Review
2017
In vivo phenotypic screening and drug repositioning are strategies developed as alternatives to underperforming hypothesis-driven… Expand
Is this relevant?
2012
2012
2(1H)-pyrimidinone,5-(3-methylphenoxy) (MLR-1023) is a candidate for the treatment of type 2 diabetes. The current studies were… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
2012
2012
MLR-1023 [Tolimidone; CP-26154; 2(1H)-pyrimidinone, 5-(3-methylphenoxy)] is an allosteric Lyn kinase activator that reduces blood… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?